期刊
BREAST CANCER RESEARCH AND TREATMENT
卷 198, 期 2, 页码 253-264出版社
SPRINGER
DOI: 10.1007/s10549-022-06837-4
关键词
Metastatic breast cancer; De novo stage IV; Metachronous metastatic breast cancer; Overall survival; Prognosis
类别
This study aimed to compare characteristics and survival of patients with de novo and metachronous metastatic breast cancer. Data from the Netherlands Cancer Registry were used to categorize patients into de novo or metachronous metastatic breast cancer groups. The study found differences in clinicopathological characteristics and survival between these two groups.
PurposeThe aim of this study was to compare characteristics and survival of patients with de novo and metachronous metastatic breast cancer.MethodsData of patients with metastatic breast cancer were obtained from the Netherlands Cancer Registry. Patients were categorized as having de novo metastatic breast cancer (n = 8656) if they had distant metastases at initial presentation, or metachronous metastatic disease (n = 2374) in case they developed metastases within 5 or 10 years after initial breast cancer diagnosis. Clinicopathological characteristics and treatments of these two groups were compared, after which multiple imputation was performed to account for missing data. Overall survival was compared for patients treated with systemic therapy in the metastatic setting, using Kaplan Meier curves and multivariable Cox proportional hazards models. The hazard ratio for overall survival of de novo versus metachronous metastases was assessed accounting for time-varying effects.ResultsCompared to metachronous patients, patients with de novo metastatic breast cancer were more likely to be >= 70 years, to have invasive lobular carcinoma, clinical T3 or T4 tumours, loco-regional lymph node metastases, HER2 positivity, bone only disease and to have received systemic therapy in the metastatic setting. They were less likely to have triple negative tumours and liver or brain metastases. Patients with de novo metastases survived longer (median 34.7 months) than patients with metachronous metastases (median 24.3 months) and the hazard ratio (0.75) varied over time.ConclusionsDifferences in clinicopathological characteristics and survival between de novo and metachronous metastatic breast cancer highlight that these are distinct patients groups.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据